Vanda Pharmaceuticals (VNDA) to Release Earnings on Thursday

Vanda Pharmaceuticals (NASDAQ:VNDA) is expected to be posting its quarterly earnings results after the market closes on Thursday, February 13th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.14) per share and revenue of $52.25 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Vanda Pharmaceuticals Stock Down 3.7 %

Shares of VNDA opened at $4.62 on Tuesday. Vanda Pharmaceuticals has a 12-month low of $3.71 and a 12-month high of $6.75. The business has a 50-day simple moving average of $4.64 and a two-hundred day simple moving average of $4.89.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the transaction, the director now owns 44,857 shares in the company, valued at $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 8.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on VNDA shares. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, February 4th. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.